# Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

> **NCT01084655** · PHASE1,PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** TAK-700
- **DRUG:** Docetaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01084655
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-01
- **Final completion:** 2016-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01084655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01084655, "Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01084655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*